Company intelligence / Profile preview
Flindr Therapeutics
Oss, Netherlandsflindrtx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing first-in-class small molecule inhibitors for precision treatment of cancer. Their lead program targets RNF31, which when inhibited destabilizes two proteins that switch cancer cells from survival to cell death.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule inhibitors
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Netherlands Cancer Institute (NCI)Oncode InstituteVlaams Institute voor Biotechnologie (VIB)
Beyond the preview
Go deeper on Flindr Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flindr Therapeutics.